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Neurodegenerative diseases refer to the selective loss of neuronal systems in patients.The diseases cause highmorbidity andmortal-
ity to approximately 22 million people worldwide and the number is expected to be tripled by 2050. Up to now, there is no effective
prevention and treatment for the neurodegenerative diseases. Although some of the clinical therapies target at slowing down the
progression of symptoms of the diseases, the general effectiveness of the drugs has been far from satisfactory. Traditional Chinese
medicine becomes popular alternative remedies as it has been practiced clinically for more than thousands of years in China. As
neurodegenerative diseases are mediated through different pathways, herbal decoction with multiple herbs is used as an effective
therapeutic approach to work on multiple targets. Gastrodia and Uncaria Decoction, a popular TCM decoction, has been used to
treat stroke inChina.Thedecoction contains compounds including alkaloids, flavonoids, iridoids, carotenoids, and natural phenols,
which have been found to possess anti-inflammatory, antioxidative, and antiapoptotic effects. In this review, we will summarize the
recent publications of the pharmacological effects of these five groups of compounds. Understanding the mechanisms of action of
these compounds may provide new treatment opportunities for the patients with neurodegenerative diseases.
1. Introduction
1.1. Neurodegenerative Diseases. Neurodegenerative diseases
are associated with high morbidity, mortality, and economic
burden to the community worldwide. It is estimated to have
22 million people worldwide suffering from these diseases
and this number is expected to be triple in western countries
by 2050 due to the increase in average life expectancy [1].
The diseases can be categorized as acute (including stroke,
brain trauma, and spinal cord injury) and chronic (including
amyotrophic lateral sclerosis (ALS), Huntington’s disease,
Alzheimer’s disease (AD), and Parkinson’s disease (PD))
diseases, which are characterized by selective loss of neuronal
systems. Increasing evidence shows that neurodegenerative
diseases aremediated by neuroinflammation, oxidative stress,
and apoptotic cell death [2, 3].
1.1.1. Role of Neuroinflammation in Neurodegenerative Dis-
eases. Neuroinflammation is the reaction of the endoge-
nous central nervous system (CNS) in response to various
pathologic events. Upon stimulation, microglia, the resi-
dent tissue macrophages, are firstly activated to represent
the first line of defense [4] by releasing proinflammatory
mediators including cytokines, chemokines, proteases, and
reactive oxygen species (ROS)/reactive nitrogen species [5–
7]. Indeed, microglial activation is beneficial to the CNS as
it controls infection, minimizes further injury, and promotes
repair. Under other circumstances, however, irresolvable
stimuli can cause highly detrimental effects to neurons by the
excess productions of proinflammatory mediators including
interleukin-1 (IL-1), IL-6, nitric oxide, monocyte chemotac-
tic protein-1 (MCP-1), prostaglandins, and tumor necrosis
factor-𝛼 (TNF-𝛼) by microglial cells [8, 9]. The stimuli that
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cause microglial overactivation can be diverse, ranging from
endotoxin (e.g., lipopolysaccharide (LPS)) and neurotoxin
(e.g., amyloid-𝛽 (A𝛽)) to neuronal death. A𝛽, implicated in
pathogenesis of AD, activates microglia to release neurotoxic
factors such as nitric oxide [10] and TNF [11].
Interleukin-1 (IL-1), existing in two distinct isoforms, IL-
1𝛼 and IL-1𝛽, is one of themost widely studied proinflammat-
ory cytokines in the brain. It is partly due to the elevated IL-
1 expression detected in patients with acute or chronic neu-
rodegenerative diseases [12]. Upon CNS damage/infection,
microglial cells produce the highest levels of IL-1 [13]. In
turn, IL-1 activates microglial and endothelial cells to pro-
duce various kinds of mediators including proinflammatory
cytokines (IL-6 and TNF-𝛼), chemokines (MCP-1), adhesion
molecules, prostaglandins, ROS, nitric oxide, and matrix
metalloproteases, which are considered to be toxic to neurons
and glial cells [14].
Tumor necrosis factor-𝛼 (TNF-𝛼) is another major medi-
ator known to be implicated in several neurodegenerative
diseases including AD, ALS, PD, and stroke [15]. In the CNS,
elevated TNF-𝛼 is synthesized by astrocytes, neurons, and
microglia upon infections/injuries [16]. TNF-𝛼 is found to
mediate its effect via its receptor TNF-R1 which augments
neuronal death through induction of caspases signalings [17].
Moreover, TNF-𝛼 can induce the productions of IL-1 and
IL-6, which can amplify the neuroinflammation process.
Endotoxin and neurotoxin-induced proinflammatory
cytokines productions have been regulated by three well-
known mitogen-activated protein kinases (MAPKs) includ-
ing extracellular signal-regulated kinase (ERK), p38, and c-
Jun N-terminal kinase/stress-activated protein kinase (JNK)
[18, 19]. MAPKs transduce the extracellular stimuli through
a cascade of protein phosphorylations, which leads to the
activation of transcription factor nuclear factor (NF)-𝜅B.
The activated NF-𝜅B is then translocated and bound to 𝜅B
binding sites in the nucleus, leading to the initiation of
transcription of proinflammatory mediators.
1.1.2. Role of Oxidative Stress in Neurodegenerative Diseases.
Oxidative stress refers to the imbalance between the produc-
tion of ROS and the ability of the cells to eliminate
them [20]. Numerous studies have provided evidence that
ROS are directly involved in oxidative damage of cellular
macromolecules, resulting in neuronal cell death [21]. ROS
including hydrogen peroxide, nitric oxide, superoxide anion,
and the highly reactive hydroxyl radicals are produced by
microglia in response to the stimulation by endotoxin (e.g.,
LPS) [22], neurotoxin (e.g., A𝛽 and 6-hydroxydopamine (6-
OHDA)) [23, 24], and environmental toxins (e.g., Rotenone)
[25]. From which, nitric oxide can react with superoxide
anion to form extremely reactive peroxynitrite, which can
indiscriminately damage neurons by promoting membrane
lipid peroxidation and by the formation of nitrotyrosine [26].
Furthermore, it stimulates the release of apoptosis-inducing
factor (AIF) from themitochondria, which subsequently trig-
gers DNA fragmentation processes [27]. Enzymatic antiox-
idants including superoxide dismutase (SOD) and catalase
(CAT) have been found to catalyze the dismutation of the
superoxide anion and breakdown of hydrogen peroxide,
respectively [28].
1.1.3. Cell Death Mechanisms. Increasing lines of evidence
indicate that neuronal cell death that occurred in various
neurodegenerative disorders ismediated by necrosis and apo-
ptosis [29]. Necrosis is a form of traumatic cell death by cyto-
plasmic swelling, nuclear dissolution, and lysis, while apop-
tosis is an orderly and compartmental dismantling of cells. In
acute neurodegenerative diseases, like ischemic stroke, cells
undergo necrosis in the core region of the ischemic infarct
when their intracellular supply of metabolic substrates (e.g.,
glucose and oxygen) is depleted. The process triggers the
generation of free radicals, glutamate, cytotoxic cytokines,
and massive calcium influx through N-methyl-d-aspartate
(NMDA) receptors and voltage-dependent calcium chan-
nels [30]. The calcium influx and ROS generation trigger the
pathogenesis of apoptosis [31]. It is executed by caspases
and regulated by the Bcl-2 protein family [32]. Caspases
are considered as the major executioners of the apoptotic
pathway [32]. Caspases-3, -6, and -7 are short prodomain
caspases predominantly activated through the action by other
proteases. Activated caspase-3 can cleave the DNA repair
enzyme poly(ADP-ribose) polymerase (PARP), which can
cause abrogation of DNA repair and depletion of NAD+ and
ATP, resulting in cell death [33]. Apoptosis is also regulated by
the Bcl-2 family of proteins [34], fromwhich gene expressions
are activated including pro- (Bad and Bax) and anti- (Bcl-
2 and Bcl-xL) apoptotic proteins. In response to apoptotic
stimuli, Bad and Bax translocate to mitochondria to initiate
the release of cytochrome c, which is able to trigger the
apoptotic signaling cascade by activating the caspase-9 and
caspase-3, resulting in nuclear fragmentation and cell death
[32]. In contrast, antiapoptotic proteins including Bcl-2 and
Bcl-xL function as repressors of cell death in the CNS due to
their abilities to block the release of cytochrome c suppress
the accumulation of ROS [35].
1.2. TCM as an Alternative Medicine for Neurodegenerative
Disease. Nowadays, there are no therapeutic drugs that can
cure AD and PD due to the incomplete understanding of
their pathogenic mechanisms. Current clinical practices to
treat AD include the usage of cholinesterase inhibitors and
glutamate modulators [36]. In addition, other approaches
including anti-inflammatory, antioxidative, and anti-A𝛽-
peptides agents have been used to mitigate the symptoms
of AD [37]. Recent therapies for PD are based mainly on
three strategies: (1) the usage of L-DOPA for compensating
the progressive degeneration of dopaminergic neurons in
the substantia nigra pars compacta [38]; (2) the identifica-
tion of non-dopaminergic drugs for alleviating nonmotor
symptoms; and (3) the development of neuroprotective and
disease-modifying compounds [39, 40].Most of these clinical
therapies on slowing down the progression of symptoms
of the neurodegenerative diseases are still in the preclinical
phase and only a few of them are in the clinical phase.
However, the efficacies of the treatments are not considered
as satisfactory [1]. For the treatment of acute ischemic stroke,
The Scientific World Journal 3
N
H
N
O
H
H
H
OO
O
N
H
N
O
H
H
H
OO
O
O
HO
O
O
N
O
NH2
NH2
(3)
(1) (2)
Figure 1: Chemical structure of alkaloids: (1) rhynchophylline; (2) isorhynchophylline; (3) leonurine.
thrombolytic agent such as recombinant tissue-plasminogen
activator is available for the patients. However, the treatments
are limited by a short therapeutic window of time and side
effects [41]. At present, there is no effective clinical treatment
that can enhance the recovery or prevent the recurrence of
stroke. It is, therefore, critical to identify the pharmacological
agents that can alleviate the neurodegenerative syndromes
with fewer side effects compared with the current therapies.
Traditional Chinese medicine (TCM) has been practiced
in health care systems for thousands of years in China.
A variety of studies have demonstrated that the herbal
formulations, herbal extracts, and active compounds derived
from Chinese herbs are effective on the in vitro and in vivo
neurodegenerative models [42, 43]. Since the pathogenesis of
neurodegenerative diseases can not be single factor-derived,
a combination of different herbs as herbal decoction could be
an effective therapeutic approach. Herbal decoction consists
of multiple crude herbs may work on multiple targets to
enhance the therapeutic effects synergistically [40].
1.3. Pharmacological Effects of Gastrodia and Uncaria Decoc-
tion (GUD) on Neurodegenerative Disease. Gastrodia and
Uncaria Decoction (GUD) is often used in TCM prescrip-
tions for stroke treatment in China. It was first described in
TCM book for clinical diagnosis and therapy, titled “New
Significance of Patterns and Treatment inMiscellaneous Dis-
eases.”There are 11 herbs in this decoction, includingRhizoma
Gastrodiae (Tian Ma), Ramulus cum Uncis Uncariae (Gou
Teng), Concha Haliotidis (Shi Jue Ming), Fructus Gardeniae
(Zhi Zi),Radix Scutellariae (HuangQin),Eucommia ulmoides
Oliver (Du Zhong), Radix Cyathulae Officinalis (Niu Xi),
Ramulus Loranthi (Sang Ji Sheng), Poria cum Radix Pini
(Fu Sheng), Caulis Polygoni Multiflori (Ye Jiao Teng), and
Herba Leonuri (Yi Mu Cao). For the stroke treatment, the
pharmacological effects of the decoction are (1) to subdue the
liver and extinguish internal wind (Tian Ma, Gou Teng, and
Shi JueMing); (2) to entice the blood downward (Niu Xi); (3)
to purge liver fire (Huang Qin and Zhi Zi); (4) to supplement
liver and kidney (Sang Ji Sheng andDu Zhong); (5) to vitalize
the blood and enhance water metabolism (Yi Mu Cao); and
(6) to pacify the restless heart (Ye Jiao Teng and Fu Sheng)
[44].
In addition, a study revealed that GUD significantly
prevented hypertension in spontaneously hypertensive rats
(SHR) model and altered the development of hypertension
[45]. Another study reported that the serum of GUD-treated
rat inhibited the proliferation of vascular smoothmuscle cells
(VSMCs) by suppressing the expressions of proliferating cell
nuclear antigen (PCNA) and c-myc, increasing nitric oxide
and decreasing endothelin-1 (ET-1) levels [46].
Neurodegenerative disorders and stroke share many
pathogenic mechanisms such as inflammation, microglial
activation, oxidative stress, impaired neurotransmission,
mitochondrial dysfunction, and apoptosis [47, 48]. Neuro-
protective agents that interfere with the biochemical cascades
would be the potential therapeutic candidates. Thus, the
combination of different active compounds from individual
herb aiming at specific pathological factors would be the
systematic approach for the treatment of neurodegenerative
diseases. In this review, the anti-inflammatory, antioxidative,
and antiapoptotic effects of some of the active pharmacolog-
ical compounds (Figures 1, 2, 3, 4, and 5) identified from
individual herb of GUD will be summarized (Table 1 and
Figure 6).
2. Alkaloids
Alkaloids, a group of naturally occurring compounds origi-
nated from plant and microbes, contain at least one nitrogen
atom in the structure. The functions of alkaloids are well
known to protect the plants frompredators and regulate plant
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Figure 2: Chemical structure of flavonoids: (4) catechin; (5) quercetin; (6) rutin; (7) baicalein; (8) baicalin; (9) wogonin; (10) oroxylin A; (11)
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Figure 4: Chemical structure of carotenoid: (15) crocetin.
growth. Its pharmacological activities have been documented
to be anticancer [49], anti-inflammatory [50], and cardiovas-
cular effects [51].
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Figure 5: Chemical structure of phenolic compounds: (16) gas-
trodin and (17) p-Hydroxybenzyl alcohol.
2.1. Rhynchophylline and Isorhynchophylline. Rhynchophyl-
line and isorhynchophylline are the two most dominant
alkaloid constituents inRamulus cumUncis Uncariae [52, 53].
Their pharmacological activities were extensively studied
which have been shown to exert anti-inflammatory [54–56],
antioxidative [57, 58], and neuroprotective [57, 59–64]
effects in CNS. Anti-inflammatory effects of rhynchophylline
and isorhynchophylline were found in primary cultured rat
corticalmicroglia. One of the investigations showed that both
rhynchophylline and isorhynchophylline reduced the pro-
duction of nitric oxide in LPS-induced rat cortical microglia
[54]. More recently, another study investigated the action
of rhynchophylline on the productions of proinflammatory
The Scientific World Journal 5
Table 1: Summary of the effects of different bioactive compounds in GUD on neurodegenerative diseases.
(a)
Alkaloids
Rhynchophylline In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
Xenopus oocytes Glutamate Inhibitory effects on NMDA receptors [60]
Hippocampal slices
Xenopus oocytes
Deprivation of
oxygen and glucose
↓ neuronal damage
Inhibitory effects on NMDA, muscarinic M1, and 5-HT2
receptors-mediated neurotoxicity
[62]
Rat cortical microglia LPS ↓ nitric oxide production [54]
Mouse N9 microglia LPS
↓ TNF-𝛼, IL1-𝛽, and nitric oxide productions
↓ ERK and p38 phosphorylations, I𝜅B𝛼 degradation, and
iNOS protein level
[55]
Rat primary microglia LPS
↓ iNOS and COX-2 mRNA levels
↓ nitric oxide, PGE2, MCP-1, TNF-𝛼, and
IL1-𝛽 productions
↓ ERK and p38 phosphorylations and I𝜅B𝛼 degradation
[56]
NT2 cells Dopamine ↓ apoptosis [61]
Rat primary cortical neurons Methamphetamine ↓ neurotoxicity [63]
Rat cerebellar granule cells Glutamate ↑ cell viability by inhibition of Ca2+ influx [59]
Rhynchophylline In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats Kainic acid-inducedepileptic seizures
↓ superoxide anions level, JNK phosphorylation, and
NF-𝜅B activation [57]
Isorhynchophylline In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
Xenopus oocytes Glutamate Inhibitory effects on NMDA receptors by acting asnoncompetitive antagonists [60]
Hippocampal slices
Xenopus oocytes
Deprivation of
oxygen and glucose
↓ neuronal damage
Inhibitory effects on NMDA, muscarinic M1, and 5-HT2
receptors-mediated neurotoxicity
[62]
N2a, SH-SY5Y, PC12 cells, and
primary cortical neurons
Differentiated human
dopaminergic neurons
Nil
Stimulate autophagy of wild-type, A53T and A30P 𝛼-syn
monomers, 𝛼-syn oligomers, and 𝛼-syn/synphilin-1
aggresomes
↓ wild-type and A53T 𝛼-syn protein expressions
[64]
Rat cortical microglia LPS ↓ nitric oxide production [54]
Mouse N9 microglia LPS
↓ TNF-𝛼, IL1-𝛽, and nitric oxide productions
↓ ERK and p38 phosphorylations, I𝜅B𝛼 degradation, and
iNOS protein level
[55]
PC12 cells A𝛽
(25–35)
↑ cell viability and GSH level
↓ intracellular ROS and MDA levels
↓ DNA fragmentation and caspase-3 activity
Stabilize mitochondrial membrane potential
Moderate Bcl-2/Bax ratio
[58]
Rat cerebellar granule cells Glutamate ↑ cell viability by inhibition of Ca2+ influx [59]
Leonurine In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
SH-SY5Y cells 6-OHDA ↓ cell death, ROS level, and Bax expression
↑ superoxide dismutase activity and Bcl-2 expression [67]
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(a) Continued.
Alkaloids
Leonurine In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats MCAO ↓ ROS level and Bax expression
↑ Bcl-2 expression [68]
Rats MCAO ↓ infarct volume and lipid peroxidation
↑ superoxide dismutase and glutathione peroxidase [69]
(b)
Flavonoids
Catechin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
Rat cerebellar granule cells Glutamate ↑ cell viability by inhibition of Ca
2+ influx [78]
Rat primary mesencephalic
cultures
MPP+
H2O2, 4-HNE,
rotenone, and
6-OHDA
↓ apoptosis
↑ cellular viability and [3H] DA uptake [75]
Catechin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats Nil ↓MOA-B activity [74]
Quercetin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
N9 microglia
PC12 cells
LPS
LPS-induced N9
microglia cells
↓ TNF-𝛼 and IL-1𝛼mRNA levels
↓ apoptosis and cell death [72]
PC12 cells 6-OHDA ↓ apoptosis and cell death
↓ nitric oxide overproduction and iNOS overexpression [73]
Rat primary mesencephalic
cultures MPP
+
↓ apoptosis [75]
Rat cortical neuronal cultures A𝛽
(1–42) ↓ cytotoxicity, protein oxidation, lipid peroxidation, and apoptosis [79]
PC12 cells MPP+
↓ apoptosis and cell death
↓ Bax and ↑ Bcl-2 expressions
↓ AIF in cytosolic and nuclear fraction
↓ cytochrome c levels in cytosolic fraction
[80]
P19 neurons H2O2
↑ neuronal viability
↓ ROS production
↓ nuclear condensation, caspase 3/7 activity, and PARP
upregulation
[76]
SH-SY5Y cells H2O2
↓ cytotoxicity and LDH release
↓ Bax and ↑ Bcl-2 expressions
↓ caspase activation
[81]
Quercetin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Zebra fish 6-OHDA ↓ dopaminergic neuron loss
↓ TNF-𝛼, IL-1𝛽, and COX-2 overexpressions [73]
Rats 6-OHDA
↑ striatal dopamine and antioxidant enzyme levels
↓ protein carbonyl content in the striatum
↑ neuronal survivability
[77]
Rats Repeated cerebralischemia
Improve spatial memory impairment
↓ neuronal death [82]
Rats pMCAO ↓ ischemic lesion
↑ GSH levels in ipsilateral striatum and cortex [83]
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(b) Continued.
Flavonoids
Rutin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS ↓ nitric oxide production
↓ iNOS gene expression [89]
SH-SY5Y cells
BV-2 microglia A𝛽42
↓ ROS production
↓ TNF-𝛼 and IL-1𝛽 productions [90]
Rutin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats 6-OHDA ↑ antioxidant enzymes activities
↓ nitric oxide level [91]
Rats Trimethyltin (TMT) ↓ IL-1𝛽 and IL-6 mRNA levels [92]
Rats Cerebral ischemia ↓ neuronal death [93]
Baicalein In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
BV-2 microglia Hypoxia ↓HIF-1 protein accumulation and transcriptional activation
↓ iNOS, COX-2, and VEGF gene expressions [97]
Primary midbrain
neuron-glia cultures LPS ↓ TNF-𝛼, nitric oxide, and superoxide productions [94]
SH-SY5Y cells 6-OHDA ↓ oxidative stress, mitochondrial dysfunction, caspase activity, andJNK activation [99]
SH-SY5Y cells 6-OHDA ↓ apoptosis [100]
HT22 mouse hippocampal
neuronal cells
Thapsigargin (TG)
and brefeldin A (BFA)
↓ apoptosis
↓ C/EBP homologous protein (CHOP) induction and ROS
accumulation
[101]
Rat glioma C6 cells H2O2
↓ ROS-mediated cytotoxic effects
Modulate ERKs activation
↑HO-1 protein expression
[102]
Primary microglia/BV-2 cells LPS/IFN-𝛾 ↓ nitric oxide production and iNOS gene expression
↓ NF-IL6 binding [98]
PC12 cells Rotenone ↓ apoptosis
↓ ROS production [103]
Baicalein In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats Controlled corticalimpact injury
Improve functional recovery
↓ contusion volumes
↓ the number of degenerating neurons
↓ TNF-𝛼, IL-1𝛽, and IL-6 mRNA and protein levels
[104]
Baicalin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS ↓ nitric oxide production
↓ iNOS and COX-2 gene expressions [118]
RAW 264.7 cells and peritoneal
macrophages LPS or IFN-𝛾
↓ nitric oxide production and iNOS expression
↓ TNF-𝛼, ET-1, and thromboxane A2 (TXA2) [106]
PC12 cells Oxygen-glucosedeprivation/H2O2
↓ ROS production
↓ 5-LOX nuclear translocation
↓ p38 phosphorylation
[107]
Baicalin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats pMCAO
↓ neurological deficit scores and cerebral infarct volume
↓ iNOS, COX-2 mRNA, and cleaved caspase-3 protein expressions
↓ TLR2/4 and NF-𝜅B expressions
[108, 109]
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(b) Continued.
Flavonoids
Rats Spinal cord injury ↓ oxidant stress, proinflammatory cytokines expressions, andapoptosis [111]
Rats
Focal cerebral
ischemic reperfusion
injury
↓ NF-𝜅B p65 level [110]
Wogonin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS ↓ PGE2 and nitric oxide productions
↓COX-2 expression and activity [112–115]
Microglia LPS
↓ nitric oxide production
↓ TNF-𝛼 and IL-6 productions
↓ NF-𝜅B activity
[116]
Microglia MCP-1 ↓ NF-𝜅B activity [117]
Wogonin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Mice LPS ↓ nitric oxide production
↓ iNOS expression [113]
Rats pMCAO ↓ infarct volumeImprove behavioral dysfunction [119]
Oroxylin A In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS
↓ nitric oxide production
↓ iNOS and COX-2 gene expressions
↓ NF-𝜅B activation
[120]
Apigenin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS ↓ COX-2 and iNOS expressions
↓ NF-𝜅B activation [123]
PBMC LPS ↓ TNF-𝛼, IL-6, and IL-1𝛽 productions [124]
J774.2 macrophages LPS ↓ TNF-𝛼 and IL-1𝛽mRNA levels [125]
BV-2 microglia LPS ↓ nitric oxide and PGE2 productions
↓ p38 and JNK phosphorylations [126]
Apigenin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Mice MCAO ↓ infarct volume
↓ the number of microglia [126]
Kaempferol In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
J774.2 macrophages LPS ↓ TNF-𝛼 and IL-1𝛽mRNA levels [125]
J774 macrophages LPS ↓ PGE2 production
↓ COX-2 and mPGES-1 mRNA levels [127]
J774 macrophages LPS ↓ nitric oxide production
↓ iNOS mRNA and protein expressions [128]
RAW 264.7 cells LPS ↓ nitric oxide, PGE2, and TNF-𝛼 productions [129]
Kaempferol In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats Transient focalcerebral ischemia
↓ nitrosative-oxidative stress, protein nitrotyrosines, and apoptotic
cell death [130]
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(b) Continued.
Flavonoids
Hyperoside In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
PC12 cells Sodium azide
↓ ROS production
↓ caspase-3 activity and Bax expression
↑ Bcl-2 expression
[133]
PC12 cells H2O2 and tert-butylhydroperoxide
↑ cell viability
↓ apoptosis [132]
Mouse peritoneal macrophages LPS ↓ TNF-𝛼, IL-6, and nitric oxide productions [131]
Hyperoside In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats MCAO ↓ infarct size and cerebral edema [134]
(c)
Iridoids
Geniposide In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
PC12 cells CoCl2
↓ apoptosis, Bax, P53, and caspase-9 expressions
↑ Bcl-2 expression [147]
PC12 cells SIN-1 ↓ oxidative damage
↑HO-1 expression [139]
PC12 cells H2O2 ↑ Bcl-2 and HO-1 expressions [140]
PC12 cells H2O2
↓ oxidative damage
↑ Bcl-2 expression [141]
Primary hippocampal neurons SIN-1 ↓ oxidative damage
↑HO-1 expression [142]
Rat hippocampal slice culture Oxygen and glucosedeprivation ↓ neuronal cell death [148]
Genipin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
N2a cells A23187 ↓ cytotoxicity [143]
N2a cells 6-OHDA ↓ neurotoxicity [144]
Primary hippocampal neurons A𝛽
(25–35) ↓ neurotoxicity [145]
N2a cells Tunicamycin
↑ cellular viability
↓ ER stress-induced upregulation of CHOP and
GRP78
[146]
RAW 264.7 cells LPS
↓ nitric oxide and PGE2 productions
↓ iNOS, COX-2, IL-6, IL-1𝛽, and TNF-𝛼
expressions
↓ NF-𝜅B activation
[136]
Rat brain microglia LPSIFN-𝛾 and A𝛽
↓ nitric oxide, TNF-𝛼, IL-1𝛽, PGE2, intracellular
ROS productions, and NF-𝜅B activation
↓ nitric oxide release
[137]
Genipin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Mice and rats Carrageenan ↓ paw edema, air pouch formation, and nitricoxide production [138]
Mice CarrageenanLPS
↓ paw edema
↓ plasma TNF-𝛼 and IL-6 productions [136]
Mice LPS ↓microglial activation [137]
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(d)
Carotenoids
Crocetin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
Isolated brain of stroke-prone
spontaneously hypertensive rat Nil ↓ ROS-mediated oxidative stress [157]
SH-SY5Y cells H2O2
↑ cellular viability
↓ ROS production and caspase-3 activation [158]
Crocetin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats 6-OHDA ↑ antioxidant activity, GSH, and dopamine levels
↓ TBARS level [159]
(e)
Natural phenols
Gastrodin In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
Cultured rat cortical neurons Hypoxia ↑ neuron survival [160]
Cultured rat hippocampal
neurons
Oxygen/glucose
deprivation and
glutamate
↓ Ca2+ and nitric oxide productions [161]
BV-2 cells LPS ↓ TNF-𝛼 and IL-1𝛽 productions
↓ iNOS and COX-2 expressions [162]
Gastrodin In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats MCAO ↓ cerebral infarct volume
↓ cerebral injury [163]
p-Hydroxybenzyl alcohol In vitro/ex vivo
Cells used (in vitro) Inducer(s) Functions References
RAW 264.7 cells LPS ↓ nitric oxide production [164]
BV-2 cells LPS ↓ nitric oxide production [165]
PC-12 cells H2O2 ↓ cell death [166]
p-Hydroxybenzyl alcohol In vivo
Type of animals (in vivo) Disease model used(in vivo) Functions References
Rats MCAO
↓ brain damage
↑ protein disulfide isomerase (PDI) and 1-Cys peroxiredoxin (1-Cys
Prx) transcription levels
[167]
Rats MCAO Modulate PDI and Nrf2 gene expressions and several neurotrophicfactors [166]
mediators and its potential mechanisms in LPS-activated
microglia. The study showed that rhynchophylline reduced
the productions of nitric oxide, prostaglandin E2 (PGE
2
),
MCP-1, TNF-𝛼, and IL-1𝛽 [56]. Besides, mRNA levels of
inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-
2 (COX-2) were also suppressed by rhynchophylline [56].
The molecular mechanisms for the inhibitions were due to
the blocking of the NF-𝜅B activation and the suppression
of ERK and p38 phosphorylations in activated microglia
[56]. Apart from rat primary microglia, rhynchophylline and
isorhynchophylline effectively suppressed the release of nitric
oxide, TNF-𝛼, and IL-1𝛽 via suppressions of iNOS protein
level, ERK and p38 phosphorylations, and degradation of
I𝜅B𝛼 in LPS-activated murine N9 microglial cell line, with
isorhynchophylline showing more potent inhibition [55].
Isorhynchophylline exerted protective effect upon oxida-
tive stress. In a recent study, isorhynchophylline was found
to possess neuroprotective effects against A𝛽-induced neu-
rotoxicity in PC12 cells [58]. The protections were due to
the reduction of intracellular ROS and malondialdehyde
(MDA) levels, induction of glutathione (GSH) level, and
stabilization of mitochondrial membrane potential [58]. In
addition, isorhynchophylline suppressed the mitochondrial
pathway of cellular apoptosis by reducing the formation of
The Scientific World Journal 11
TLR4
Degradation
JNK p38 ERK
LPS
IRAK
COX-2
IL-6
p65p50
p65p50 mRNA
iNOS
NO
Caspase-1
mRNA
A, F
A, F
F
A
A, F, N
A, F, N
A, F, I
A, F, I
A, F, C
A, F, C
A, F, C
F, N
A, F, I I
A, F, I, N
A, F, I, N
Activated microglia
NF-𝜅B
NF-𝜅B
TNF-𝛼
PGE2
IL-1𝛽
Cleaved IL-1𝛽
I𝜅B-𝛼
ROS
Caspase-9
Apaf-1
Bcl-2
Bax
Cyto C
DNA
Damage
Caspase-3/7
SOD
GSH
F
I
Ca2+
H2O2
H2O
Damaged neuron
A:
N:
C:
I:
F:
alkaloids
flavonoids
iridoids
carotenoids
natural phenols
Protein Receptor
Inducer
Compound
Activate
Inhibit
Trigger
Chemical products
Mitochondrion
Ion channel
O2
−
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DNA fragmentation and the activity of caspase-3 as well as
moderating the ratio of Bcl-2/Bax expression [58].
Rhynchophylline was found to have neuroprotective
effects upon the induction of neurotoxin. Dopamine-induced
apoptosis of NT2 neurons has been suppressed by rhyn-
chophylline [61]. In another study using rat primary cor-
tical neurons, rhynchophylline protected against metham-
phetamine (MA)-induced neurotoxicity [63]. Excessive acti-
vation of NMDA subtype glutamate receptors by glutamate
triggered neuronal cell damage in the brain [65]. Rhyn-
chophylline and isorhynchophylline were shown to suppress
glutamate-induced neuronal death in rat cerebellar granule
cells by inhibition of Ca2+ influx [59] and they both acted
as noncompetitive antagonists of NMDA receptor expressed
in Xenopus oocytes [60]. Further investigation using depri-
vation of oxygen and glucose-induced neuronal damage
in rat hippocampus showed that both rhynchophylline
and isorhynchophylline suppressed the in vitro ischemia-
induced neuronal damage [62]. The inhibitory effects might
attribute to the interactions of rhynchophylline and isorhyn-
chophylline with neurotransmitters receptors other than the
NMDA subtype such as muscarinic M
1
and 5-HT
2
receptors
[62].
Aberrant expressions and aggregation of 𝛼-synuclein (𝛼-
syn) in neurons are the pathogenic factors of PD [66].
A recent study suggested that isorhynchophylline induced
autophagy in different neuronal cell lines including N2a, SH-
SY5Y, and PC12 cells and also in primary cortical neurons
[64].The induction of autophagywas due to the promotion of
clearance of wild-type, A53T and A30P 𝛼-syn monomers, 𝛼-
syn oligomers, and𝛼-syn/synphilin-1 aggresomes in neuronal
cells via the autophagy-lysosome pathway [64]. Besides,
isorhynchophylline reduced the wild-type and A53T 𝛼-syn
protein expressions in differentiated human dopaminergic
neurons [64].
The anti-inflammatory effect of rhynchophylline has been
demonstrated in an in vivo model. In a kainic acid-induced
seizures rat model, rhynchophylline has the antiepileptic
effects associated with the reduction of the superoxide anions
levels, JNK phosphorylation, and NF-𝜅B activation [57].
2.2. Leonurine. Leonurine, another alkaloid present inHerba
Leonuri, has been demonstrated as an effective cardiovas-
cular agent in preclinical studies. Its neuroprotective effect
on neuronal cells has also been documented [67–69]. In
an in vitro study, leonurine protected SH-SY5Y cells from
cytotoxicity and apoptosis induced by 6-OHDA [67]. The
underlying mechanisms were due to its anti-inflammatory
and antiapoptotic effects by ameliorating intracellular ROS
generation, downregulating of proapoptotic Bax, and upregu-
lating of antiapoptotic Bcl-2 in bothmRNA and protein levels
[67]. The therapeutic potential of leonurine on brain injury
has been demonstrated using transient rat middle cerebral
artery occlusion (MCAO) models. With the pretreatment of
leonurine, the infarct volume of the neurological impairment
of rats was found to be reduced after MCAO [68]. Moreover,
the mitochondrial ROS was reduced as a result of leonurine
treatment, indicating that leonurine possessed antioxidant
activity to exert its antiapoptotic effect by preserving mito-
chondrial function [68]. A similar study also demonstrated
the antioxidant effect of leonurine, which reduced the infarct
volume and improved the neurological deficit of rats after
MCAO [69]. At the same time, it also increased the activities
of antioxidant enzymes including superoxide dismutase and
glutathione peroxidase [69].
3. Flavonoids
Flavonoids represent the largest group of plant-specific sec-
ondary metabolites for flower coloration. They chemically
consist of 15 carbon atoms arranged in C6-C3-C6 skele-
ton. They possess a wide spectrum of biological activities
including anti-inflammatory, anticancer, and antioxidative
effects [70]. The antioxidative effect may result from direct
scavenging of ROS, high propensity to electron transfer, and
chelating ferrous l ions by flavonoids [71].
3.1. Quercetin and Catechin. Quercetin and catechin are
widely studied for their potential pharmacological properties
on neurodegenerative diseases based on their underlying
mechanisms related to anti-inflammatory [72, 73], antioxida-
tive [74–77], and neuroprotective [76–83] effects on both in
vitro and in vivo neural damage models.
Quercetin was reported to have anti-inflammatory effects
on LPS-induced N9 microglial cells by suppressing IL-1𝛼
and TNF-𝛼 mRNA levels [72]. Moreover, quercetin reduced
inflammation-mediated apoptotic neuronal cell death in
the microglial-neuronal coculture system [72]. In addition,
quercetin inhibited overproduction of nitric oxide and over-
expression of iNOS in dopaminergic neurotoxin 6-OHDA-
induced PC12 cells [73].
Antioxidative effects of flavonoids associated with neural
diseases have been extensively studied. In the rat primary
cultures, both quercetin and catechin protected the mes-
encephalic cultures from oxidative insult by N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridinium hydrochloride (MPP+)
[75]. Catechin increased the cellular viability and [3H] DA
uptake by reducing the injury produced by hydrogen per-
oxide (H
2
O
2
), 4-hydroxynonenal (4-HNE), rotenone, and
6-OHDA [75]. Most recently, a study using P19 neurons
obtained by the differentiation from mouse teratocarcinoma
P19 cells was investigated. The study showed that quercetin
increased the neuronal viability by diminishing ROS gener-
ation and inhibiting nuclear condensation, caspases-3 and -
7 activities, and poly(APD-ribose) polymerase upregulation
under H
2
O
2
-induced oxidative stress [76].
Flavonoids were found to possess antioxidant activities
[84] and exert protective effects on neuronal cells from
oxidative stress-induced neurotoxicity [75, 85]. Catechin was
proven to exert protective effects against glutamate-induced
neuronal death in cultured rat cerebellar granule cells by
inhibiting Ca2+ influx [78]. Besides, more investigations
were focused on the neuroprotective effects of quercetin in
neuronal cells. One of the studies using rat cortical neu-
ronal cultures showed that quercetin significantly attenu-
ated A𝛽
(1–42)-induced cytotoxicity, protein oxidation, lipid
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peroxidation, and apoptosis [79]. Apart from the primary
cultures, oxidative stress was applied to neuronal cell lines
to evaluate the effects of quercetin on the apoptotic cascades.
Quercetin was found to suppress the apoptotic neuronal cell
death by inhibiting the activation of caspase cascade through
moderating the expression of proapoptotic gene (Bax) and
antiapoptotic gene (Bcl-2) inMPP+- andH
2
O
2
-inducedPC12
and SH-SY5Y cells, respectively [80, 81].
Quercetin and catechin have been investigated to demon-
strate their neuroprotective properties in the in vivo model.
Catechin was found to attenuate monoamine oxidase B
(MAO-B) activity in rat brain which provided protection
against oxidative neurodegeneration [74]. In a repeated cere-
bral ischemia rat model, quercetin improved spatial mem-
ory impairment and decreased neuronal cell death in the
hippocampal CA1 area [82]. Moreover, liposomal quercetin
reduced cerebral damage provoked by permanent MCAO
(pMCAO) by protecting against ischemic lesions and increas-
ing GSH levels in ipsilateral striatum and cortex in rats [83].
Besides, in the 6-OHDA-induced rat model of PD, quercetin
defended against oxidative stress and reduced dopaminergic
neuronal loss by increasing striatal dopamine and antioxidant
enzyme levels together with decreasing protein carbonyl con-
tent in striatum [77]. Recently, zebra fish has been used as a
PD disease model. Quercetin prevented 6-OHDA-stimulated
dopaminergic neuron loss by downregulating the overexpres-
sions of IL-1𝛽, TNF-𝛼, and COX-2 in zebra fish [73].
Despite the extensive studies of quercetin in various in
vitro and in vivo neural disease models, the neuroprotective
effect of quercetin remains controversial due to its inability
to cross the blood-brain barrier under in vivo conditions
[86, 87]. More mechanistic studies have to be investigated in
order to confer the conclusions.
3.2. Rutin. Rutin, comprising quercetin and disaccharide
rutinose, is a member of flavonoids also called vitamin P
present inHerba Leonuri. It is regarded as an important nutri-
tional supplement due to the pharmacological properties
including anticarcinogenic, cardioprotective, antioxidant,
and anti-inflammatory activities [88].The anti-inflammatory
activity of rutin has been well documented in several studies.
In vitro, rutin inhibited LPS-induced nitric oxide production
and iNOS gene expression in a concentration-dependent
manner in RAW 264.7 cells [89]. It was found to dose depen-
dently attenuate A𝛽
42
-induced cytotoxicity in SH-SY5Y neu-
roblastoma cells by inhibiting the formation of ROS andnitric
oxide through the reduction of iNOS activity [90], suggesting
that it can be used to treat AD. Furthermore, rutin modu-
lated the production of proinflammatory cytokines including
TNF-𝛼 and IL-1𝛽 in A𝛽
42
-induced BV-2 microglia [90].
The neuroprotective effect of rutin was investigated
in 6-OHDA-induced PD rat model. Rutin showed anti-
inflammatory effect by reducing the productions of TNF-
𝛼, IL-1𝛽, and nitric oxide as well as the expression of iNOS
in 6-OHDA treated rats [91]. Moreover, rutin suppressed
trimethyltin (TMT)-induced microglial activation by reduc-
ing the mRNA levels of IL-1𝛽 and IL-6, which resulted
in the reduction of inflammation or neuron loss in the
hippocampus of rats [92]. Another study also demonstrated
that rutin reduced cerebral ischemia-induced neuronal death
in the hippocampal region CA1 of rats [93]. The results
illustrate that rutin is a potent anti-inflammatory agent for
treating neurodegenerative diseases.
3.3. Baicalein. Baicalein, a flavonoid originally isolated from
the root of Scutellaria baicalensis Georgi, has various biolog-
ical activities including anti-inflammatory [94], antioxidant,
antiviral [95], and antifibrotic effects [96]. In vitro, baicalein
possessed anti-inflammatory effect by inhibiting hypoxia-
inducible factor-1 alpha (HIF-1𝛼) protein accumulation and
HIF-1 transcriptional activation on hypoxia-induced BV2
microglia [97]. Moreover, it suppressed the expressions of
iNOS, COX-2, and VEGF by inhibiting ROS and PI3-
kinase/Akt pathway on hypoxia-induced BV2microglia [97].
Using LPS as an inducer, baicalein was found to almost com-
pletely block the activation of microglia by attenuating the
excessive productions of TNF-𝛼 and free radicals including
nitric oxide and superoxide [94]. Baicalein was also found
to inhibit LPS/IFN-𝛾-induced nitric oxide production and
activation of iNOS gene expression in primary microglia and
BV-2 cells, through the inactivation of NF-IL6 [98].
In terms of antioxidative effect, baicalein protected the
neuronal SH-SY5Y cells from 6-OHDA-induced cell apop-
tosis through the suppressions of caspase-3, caspase-9, and
phospho-JNK activation as well as ROS generation [99, 100].
Baicalein protected HT22mouse hippocampal neuronal cells
against thapsigargin (TG) and brefeldin A (BFA)-induced
apoptosis through the inhibition of ROS accumulation [101].
Moreover, a study demonstrated that baicalein inhibited
ROS-mediated cytotoxic effects through the modulation of
ERKs activation and the induction of heme oxygenase-1
(HO-1) protein expression on H
2
O
2
-induced rat glioma C6
cells [102]. Another study found that baicalein suppressed
neurotoxin rotenone-induced apoptosis and inhibited the
accumulation of ROS on rotenone-induced toxicity in PC12
cells [103].
In vivo, baicalein has been demonstrated to improve
functional recovery and reduce contusion volumes of rats
after controlled cortical impact injury [104]. Moreover, it
also significantly reduced the mRNA and protein levels of
proinflammatory cytokines including TNF-𝛼, IL-1𝛽, and IL-6
[104]. In general, the in vitro and in vivo data were suggestive
of the potential role of baicalein in protecting the brain cells
from apoptosis.
3.4. Baicalin. Baicalin, a flavonoid compound isolated from
Scutellaria baicalensis Georgi, has been widely used in China
to treat the inflammatory diseases and ischemic stroke for
thousands of years. In vitro, RAW 264.7 cells induced by LPS
have been used as a model to study the anti-inflammatory
effect of baicalin. One of the studies demonstrated that
baicalin inhibited nitric oxide production and iNOS gene
expression [105]. Another study found that baicalin inhibited
the productions of proinflammatory mediators including
TNF-𝛼, ET-1, and thromboxane A2 (TXA2) [106]. Moreover,
baicalin possessed antioxidative effect by reducing ROS
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production, inhibiting 5-LOX translocation to the nuclear
envelope, and inhibiting p38 phosphorylation in oxygen-
glucose deprivation/H
2
O
2
-induced PC12 cells [107].
In vivo, baicalin was found to reduce neurological deficit
scores and cerebral infarct volume of Sprague-Dawley rats
after pMCAO [108]. The underlying mechanisms were due
to the anti-inflammatory effect of baicalin that significantly
reduced the expressions of iNOS and COX-2 mRNA levels
in rat brain [108]. Moreover, it also possessed antioxidative
effect to inhibit neuronal apoptosis and the expression of
cleaved caspase-3 protein [108]. Tu et al. found that baicalin
reduced the expression of TLR2/4 and NF-𝜅B and attenuated
the serum content of proinflammatory cytokines including
TNF-𝛼 and IL-1𝛽 [109]. Another study demonstrated that rats
treated with baicalin show significant reduced neurological
deficit scores and infarction volume [110]. Further investi-
gations revealed that the neuroprotective effects of baicalin
were due to the inhibition of NF-𝜅B p65 [110]. Similar study
demonstrated that baicalin inhibited the transcription of NF-
𝜅B and the generation of inflammatory mediator TNF-𝛼 in
the injured spinal cord tissue of rats [111]. Moreover, baicalin
reduced the expression of Bax and increased the expression
of Bcl-2 [111].
3.5. Wogonin. Wogonin is one of the flavonoids from the
root of Scutellaria baicalensis Georgi. The anti-inflammatory
effect of wogonin has been recognized for a long time. A
previous study demonstrated that the mechanisms of anti-
inflammatory effect of wogonin involved the modulation of
mediators and enzyme systems including cytokines, COX-
2, and iNOS [112–116]. For instance, wogonin inhibited
LPS-induced COX-2 expression and PGE
2
production in
RAW 264.7 cells [112]. In addition, wogonin decreased the
productions of proinflammatory cytokines including TNF-
𝛼 and IL-6 in LPS-induced microglia [116]. Furthermore,
wogonin completely suppressed the activity of NF-𝜅B in
MCP-1-stimulated microglia [117]. Wogonin was found to
inhibit nitric oxide production through the suppression of
iNOS on LPS-induced RAW 264.7 cells [118].
The neuroprotective effect of wogonin was demonstrated
using animal models. Wogonin was found to reduce the total
infarction volume and improve the behavioral deficits in rats
after pMCAO [119]. Another study also demonstrated that
wogonin exerted inhibitory activity on LPS-induced nitric
oxide production through the suppression of iNOS expres-
sion in Balb/c mice [113].
3.6. Oroxylin A. Oroxylin A, being one of the principle
components in Scutellaria baicalensis Georgi, possesses
strong anti-inflammatory effect by inhibiting LPS/Bcl-induc-
ed iNOS and COX-2 gene expressions in RAW 264.7 cells
[120].Themechanismwas due to the inhibition of the binding
of transcription factor NF-𝜅B to the iNOS promoter [120].
Furthermore, oroxylin A inhibited 12-lipoxygenase in human
platelets [121].
In vivo, pretreatment of oroxylin A ameliorated the
memory impairment of A𝛽
(25–35)-induced mice, through the
reduction of astrocyte and microglia activations and iNOS
expression [122]. The result revealed that oroxylin A can be
potentially used for treating PD.
3.7. Apigenin. The anti-inflammatory activity of apigenin,
presents in Herba Leonuri, has been well studied. Apigenin
inhibited the protein and mRNA expressions of COX-2 and
iNOS in LPS-inducedRAW264.7 cells through the inhibition
of I𝜅B kinase activity [123]. Apigenin also inhibited the
productions of proinflammatory cytokines including TNF-𝛼,
IL-6, and IL-1𝛽 on LPS-stimulated human peripheral blood
mononuclear cells [124]. It also reduced the mRNA levels
of TNF-𝛼 and IL-1𝛽 in LPS-induced J774.2 macrophages
[125]. Apigenin inhibited the production of nitric oxide and
PGE
2
by suppressing the expression of iNOS and COX-
2 protein, respectively. Moreover, apigenin suppressed the
phosphorylations of p38 and JNK but not the activity of ERK
[126].
In vivo, apigenin significantly reduced the infarct vol-
ume of mice in MCAO model. Also, it inhibited microglial
activation, resulting in the reduction of damage in various
neurodegenerative diseases [126].
3.8. Kaempferol. Kaempferol can be found from Herba
Leonuri, possessing anti-inflammatory activity as illustrated
using LPS-induced J774.2 macrophages as the model. The
compound was found to decrease the number of TNF-𝛼
mRNA copies and inhibit IL-1𝛽 gene expression in LPS-
activated J774.2 macrophages [125]. Besides, it also effectively
inhibited the productions of PGE
2
and nitric oxide as well as
downregulated microsomal PGE
2
synthase-1 (mPGES-1) and
iNOS expressions [127, 128].Themechanisms were due to the
inhibition of the activation of NF-𝜅B and signal transducer
and activator of transcription 1 (STAT-1) [128]. In combina-
tion with another flavonoid chrysin, kaempferol was found to
significantly synergize their inhibitory effect on nitric oxide,
PGE
2
, and TNF-𝛼 secretions in LPS-induced RAW 264.7
macrophages [129]. The in vivo experiment demonstrated
that kaempferol protected the rat brain from damage in
the temporal-frontal areas of neocortex and striatum [130].
Kaempferol also protected the rat brain against nitrosative-
oxidative stress after ischemia/reperfusion, as shown by
nearly complete protection against the increase of protein
nitrotyrosines, and also afford strong protection against the
increase of apoptotic cell death and biochemical markers of
apoptosis including caspase-9 activity and poly(ADP-ribose)
polymerase degradation [130].
3.9. Hyperoside. Hyperoside (Hyp, quercetin-3-O-galacto-
side), a flavonoid compound, is usually found in Herba
Leonuri. Hyperoside was shown to exert an anti-inflammato-
ry action through suppressing the productions of TNF-𝛼,
IL-6, and nitric oxide in LPS-induced mouse peritoneal
macrophages [131].The antioxidative effect of hyperoside was
demonstrated by investigating its effects on H
2
O
2
and tert-
butyl hydroperoxide-induced PC12 cytotoxicity. The result
showed that hyperoside efficiently prevented PC12 cells from
shrinking and turning against apoptosis as indicated by
the decrease of extracellular lactate dehydrogenase levels
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[132]. The antiapoptotic effect of hyperoside was found to
be partially dependent on suppressing the ROS production,
inhibiting the caspase-3 activity [133]. It was also associated
with increasing the expression of the antiapoptotic protein
Bcl-2 and decreasing the expression of proapoptotic protein
Bax in sodium azide-mediated PC12 cells [133]. In vivo,
hyperoside reduced the infarct sizes and water content, and
neurology score of the rat brain underwent focal cerebral
ischemia reperfusion injury [134].
4. Iridoids
Iridoids, the secondary metabolites found in a wide variety
of plants, are monoterpenes biosynthesized from isoprene.
Chemically, they consist of a cyclopentane ring fused to a
six-membered oxygen heterocycle. The iridoids produced by
plants are primarily used to protect against herbivores or
to prevent the plants against infection. This group of com-
pound has attracted much interest for medicinal use because
of their pharmaceutical activities including cardiovascular,
anti-inflammatory, neuroprotective, antitumor, antiviral, and
immunomodulatory activities [135].
4.1. Genipin and Geniposide. Iridoid compounds found in
Gardenia jasminoides such as genipin and geniposide have
been demonstrated to have diverse pharmacological activities
including anti-inflammatory [136–138], antioxidative [139–
142], neuroprotective [143–148], and neurotrophic [149–152]
effects.Thus, the iridoid compounds have been considered to
be the treatment of various neurological disorders.
Genipin, the aglycone of geniposide, has been exam-
ined to evaluate its anti-inflammatory properties in the in
vitro experiments. Genipin dose dependently inhibited the
productions of NO and PGE
2
as well as the expressions of
iNOS, COX-2, IL-6, IL-1𝛽, and TNF-𝛼 via downregulation of
NF-𝜅B activation in LPS-stimulated RAW 264.7 macrophage
[136]. Besides, microglial activations were reduced by genipin
through the inhibitions of nitric oxide, TNF-𝛼, IL-1𝛽, PGE
2
,
intracellular ROS productions, and NF-𝜅B activation in LPS-
stimulated rat brain microglial cells [137]. Other than LPS,
more pathophysiological stimuli A𝛽 in combination with
IFN-𝛾 were used to stimulate the microglial cells. Both
pretreatment and posttreatment of genipin reduced nitric
oxide release in A𝛽 and IFN-𝛾 stimulated microglia [137].
Recently, genipin has been isolated from Eucommia
ulmoides Oliver in our laboratory. The biological effect of
genipin was studied and the results showed that genipin dose
dependently inhibited the productions of nitric oxide and
TNF-𝛼 as well as iNOS mRNA levels in LPS-stimulated BV-2
mouse microglial cells (data not shown). The inhibition was
due to the suppressive effect of genipin on PI3K/Akt activa-
tion.Moreover, genipin protectedNeuro-2a cells against neu-
rotoxicity stimulated by the conditioned media transferred
from LPS-challenged BV-2 cells.
Oxidative stress in brain is associated with the poten-
tial causative factor of age-related neurodegenerative disor-
ders [153]. Compounds with capability to induce endoge-
nous antioxidative proteins were considered as a therapeu-
tic strategy for attenuating the oxidative damage and cell
death in the brain. Geniposide was able to protect against
3-morpholinosydnonimine hydrochloride (SIN-1)-induced
oxidative stress by enhancing HO-1 expression in both PC12
cells and primary hippocampal neurons [139, 142]. Genipo-
side also exerted protective effect against H
2
O
2
by inducing
Bcl-2 expression via MAPK and PI3K signaling pathways in
PC12 cells [140, 141].
As the consequence of oxidative stress, induction ofmito-
chondrial-mediated apoptosis is correlated with the devel-
opment of neurodegenerative diseases. A number of stud-
ies focused on the regulation of mitochondrial pathways
including the apoptosis-related protein expressions and the
neurotoxin-induced neuronal cell death. Cobalt chloride
(CoCl
2
)-induced cell death in PC12 cells, which mimic
hypoxia-induced neuronal cytotoxicity, was protected by
geniposide through decreasing the expression of Bax, P53,
and caspase-9 while increasing the expression of Bcl-2 [147].
Besides, in the model of rat hippocampal slice culture,
geniposide protected neuronal cell death from oxygen and
glucose deprivation [148]. In addition, genipin protected neu-
ronal cells against cytotoxicity induced by various neurotoxic
agents including A𝛽
(25–35) [145], 6-OHDA [144], A23187 (a
calcium ionophore) [143], and tunicamycin [146].
Anti-inflammatory effects of genipin have been evaluated
in the in vivo models. Neuroinflammation induced by sys-
temic administration of LPS in mouse has been inhibited by
genipin through the reduction of TNF-𝛼 and IL-6 produc-
tions in plasma [136]. Genipin could also provide neuropro-
tection by reducing the productions of various neurotoxic
molecules from activated microglia [137]. Moreover, genipin
effectively inhibited carrageenan-induced paw edema [136,
138], air pouch formation, and nitric oxide content in the
exudates of mouse models [138].
5. Carotenoids
Carotenoids are tetraterpenoids naturally occurring in plants
and other photosynthetic organisms. The structure of caro-
tenoids is composed of a central carbon chain of alternating
single and double bonds. The conjugated double bonds
are well known to be responsible for the pigments of the
carotenoids.They possessed antioxidant [154], cardiovascular
[155], and anticancer [155] effects as well as reduced the risk
of neurodegenerative diseases [156].
5.1. Crocetin. Crocetin is a natural carotenoid compound
found in Gardenia jasminoides. Antioxidant effects of cro-
cetin have been evaluated in both in vitro and in vivomodels.
In onemodel using stroke-prone spontaneously hypertensive
rat (SHRSP), crocetin reduced oxidative stress in the isolated
brain by acting as a scavenger of ROS [157]. In another study
using SH-SY5Y cells, crocetin protected against cellular apop-
tosis by repressing ROS production and decreasing caspase-3
activation [158]. Neuromodulatory effect of crocetin has been
investigated in the in vivo experiment. Report showed that
pretreatment of crocetin enhanced the antioxidant enzyme
activity, GSH, and dopamine levels whereas attenuated thio-
barbituric acid reactive substance (TBARS) level in 6-OHDA-
induced rats [159].
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6. Phenolic Compounds
Phenolic compounds are believed to be one of themost wide-
ly occurring groups of phytochemicals throughout the plant
kingdom. These compounds contain at least one aromatic
ringwith one ormore hydroxyl groups attached.They contain
hydrogen or electron-donating groups to interact with the
radicals, resulting in antioxidant activities.
6.1. Gastrodin. Gastrodin is the main component isolated
from the rhizome of Gastrodia elata. This compound pos-
sessed strong anti-inflammatory and antioxidant effects [160–
163]. In vitro, pretreatment of gastrodin has been demon-
strated to reduce the neurotoxicity on hypoxia-induced
rat cortical neurons [160]. It also protected against oxy-
gen/glucose deprivation and glutamate-inducedneuronal cell
death in cultured rat hippocampal neurons by inhibitingCa2+
and nitric oxide productions [161]. Gastrodin significantly
reduced the protein and mRNA expression levels of iNOS,
COX-2, TNF-𝛼, and IL-1𝛽 in LPS-induced BV-2 cells [162].
Furthermore, levels of phosphorylated ERK1/2, JNK, and p38
MAPKs were significantly reduced by the pretreatment of
gastrodin in LPS-stimulated microglial cells [162].
In vivo, gastrodin decreased the volume of cerebral
infarction and ameliorated the cerebral injury in the rats of
cerebral ischemia reperfusion [161, 163]. The studies revealed
that gastrodin had a neuroprotective effect against neurode-
generative diseases.
6.2. p-Hydroxybenzyl Alcohol. p-Hydroxybenzyl alcohol is
one of the major components in Gastrodia elata Blume (GE).
It incorporated with copolyoxalate to exert excellent antiox-
idant activity by inhibiting nitric oxide production through
the suppression of iNOS expression in LPS-activated RAW
264.7 cells [164]. Without copolyoxalate, p-Hydroxybenzyl
alcohol inhibited nitric oxide production through the sup-
pression of iNOS expression in LPS-activatedBV-2 cells [165].
Moreover, p-Hydroxybenzyl alcohol also prevented PC12 cell
death induced by H
2
O
2
[166].
In vivo, p-Hydroxybenzyl alcohol provided neuropro-
tection by preventing brain damage through the increased
expression of genes encoding antioxidant proteins including
protein disulfide isomerase (PDI) and 1-Cys peroxiredoxin (1-
Cys Prx) after transient focal cerebral ischemia in the rat brain
[167]. Moreover, pretreatment of p-Hydroxybenzyl alcohol
promoted functional recovery as indicated by the neurolog-
ical severity score [166]. It also increased the expressions of
PDI, nuclear factor-E2-related factor 2 (Nrf2), and several
neurotrophic factor genes including glial cell line-derived
neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF), nerve growth factor (NGF), and myelin
basic protein (MBP) genes [166]. The results indicate that p-
Hydroxybenzyl alcohol can protect against neuroinflamma-
tion and brain damage.
7. Conclusions
The unsatisfactory outcome of existing drugs leads to the
exploration of alternative medicines for treating acute and
chronic neurodegenerative diseases. Traditional Chinese
medicines used as alternative medicines are gaining more
attention in western countries for curing various kinds of
diseases.They are believed to be empirically effective and safe
for thousands of years. With the help of modern experiment-
based research, the compounds that are responsible for the
biological effects of the herbs are isolated and their molecular
modes of action are also characterized. In this review, we
summarize the pharmacological effects of five groups of com-
pounds including alkaloids, flavonoids, iridoids, carotenoids,
and natural phenols from GUD. These compounds exert
strong anti-inflammatory effect by inhibiting the production
of cytokines, chemokines, and proteases in neuronal cells.
In addition to the anti-inflammatory effect, they also exert
strong antioxidative and antiapoptotic effects by reducing the
generation of ROS, resulting in the reduction of necrosis and
apoptosis of the neuronal cells.
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